Cantrixil
Fallopian Tube Neoplasms
Kazia Therapeutics LimitedSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Fallopian Tube Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Eli Lilly and Company | Phase 3 | BB |
Inno-206 Eli Lilly and Company | Phase 3 | BB |
Mirvetuximab Soravtansine Eli Lilly and Company | Phase 3 | B |
Trabectedin Janssen Research & Development, LLC | Phase 3 | B |
Sofetabart Mipitecan Eli Lilly and Company | Phase 3 | B |
View all 39 →
Same molecule, other indications
Cantrixil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →